Leuprorelin Acetate
Phase 1
Leuprorelin Acetate is one of 48 therapeutic programs targeting Endometriosis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
60 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Danocrine
SanofiApproved
Bayer Aspirin
BayerApproved
Orilissa
AbbViePhase 3
IC-Green
PProvepharm SAS
Approved
Estrace
Novo NordiskApproved
Ketalar
AAultman Health Foundation
Approved
Jadelle
IItalian Network for Tumor Biotherapy Foundation
Approved
Zocor
OOrganon and Co
Approved
Trelstar
OOncoVerity, Inc.
Approved
Implanon
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Leuprorelin Acetate. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]